 | |||||||||||||||
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
 |
News item posted on 2018-04-03
Steve Fesik expands partnership with Boehringer Ingelheim
CSB researcher Steve Fesik is launching a new partnership with Boehringer Ingelheim to discover and develop cancer therapies targeting MCL1. This is the third such partnership between the pharmaceutical giant and the Fesik lab. Congratulations!
Read the complete press release here.
Author: Karen D. Davis